Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.
about
Changing strategies for target therapy in gastric cancerA phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer.Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.New and emerging combination therapies for esophageal cancer.Current status of targeted therapies in advanced gastric cancer.Novel targeted agents for gastric cancer.Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma.Evolving treatments for advanced gastric cancer: appraisal of the survival trend.Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?Latest developments and emerging treatment options in the management of stomach cancer.A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.
P2860
Q26774513-D41EA795-C58C-4EC0-BBB2-A3CB19009AB1Q33421868-D91BA8EC-EC3A-41C9-B192-1564832C9D08Q35632548-6B86518D-91BA-4E24-8A77-D6B0736F0757Q36996728-762BA205-0569-49BD-AD07-C0EF00FAB672Q37996448-18222C8C-9536-4439-BD95-7FE7B182D5E4Q38019657-92356B60-BDA1-41AC-95AB-A5F31BE37D31Q38704834-0707F700-505A-4C51-BFE4-7ED9AE122941Q38823374-DA5E985B-D085-4877-88CF-3161A227217CQ38939088-A9F21536-A961-484D-956B-DA67DF3BFB08Q41898734-9BCC3714-9298-4E84-A11F-3CD80CF68556Q47121100-71E2EA9F-CE31-4B3C-9882-0F420E701BDA
P2860
Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Biweekly cetuximab and irinote ...... viously treated with platinum.
@en
Biweekly cetuximab and irinote ...... viously treated with platinum.
@nl
type
label
Biweekly cetuximab and irinote ...... viously treated with platinum.
@en
Biweekly cetuximab and irinote ...... viously treated with platinum.
@nl
prefLabel
Biweekly cetuximab and irinote ...... viously treated with platinum.
@en
Biweekly cetuximab and irinote ...... viously treated with platinum.
@nl
P2093
P2860
P50
P1433
P1476
Biweekly cetuximab and irinote ...... eviously treated with platinum
@en
P2093
Helle A Jensen
Karin De Stricker
Katrine R Schoennemann
Lene W Vestermark
Tine P Hansen
P2860
P2888
P304
P356
10.1007/S10120-011-0031-7
P577
2011-03-17T00:00:00Z